Skip to main content
. Author manuscript; available in PMC: 2015 Jun 4.
Published in final edited form as: Invest New Drugs. 2013 Dec 3;32(3):452–464. doi: 10.1007/s10637-013-0047-4

Table 5.

Plasma DCA trough and urinary maleylacetone concentrations

Value Plasma DCA (μg/ml) Urinary MA (mg/g C)
Mean 62.9 9.5
Median 48.0 4.3
Stdev 65.5 10.0
Cmin 2.9 1
Cmax 281 45
N 21 21

Samples were obtained at the dosing interval in the eight patients who completed at least one DCA treatment cycle and were analyzed as described in the Methods. MA concentrations expressed as mg/g creatinine. Cmin and Cmax denote the minimum or maximum plasma or urinary concentration, respectively, measured for each analyte. N denotes the number of samples